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Background: This project was conducted to investigate whether the concerns
that researchers have about including terminally ill patients in research were
shared by a sample of terminally ill patients.
Methods: Twenty-two patients admitted to a hospice participated in
semistructured interviews; 18 patients had advanced malignant disease and
13werewomen; their ages ranged from28 to 93 years. The interview transcripts
were analysed for common themes and particular attention was paid to the
reasons patients gave for their views.
Results: All the patients wanted to participate in research. Patients advanced
one or more of several reasons for participation, the commonest being altruism,
enhancement of a sense of personal value, the assertion of persisting autonomy
and the value they placed on a commitment by doctors to optimising care by
research. They rejected the view that their consent might be non-autonomous
and put forward consistent views about what they considered relevant to
consent.
Conclusions: Our patients did not share the concerns of ethicists about the
difficulties and hazards of research with the terminally ill. These patients’ views
are not reflected in the professional consensus.
Introduction
This article presents a descriptive qualitative analysis of the
viewsof somedyingpatients about research. Palliative care
research is widely perceived to be ethically problematic.1–6
This would itself raise ethical concerns if the difficulties of
including terminally ill patients in research impaired their
treatment.7 We undertook this study because some of
the perceived problems of research with terminally ill
subjects arise from what the terminally ill are believed
by others to think and feel and we thought that the termi-
nally ill themselves might have contributions to make to
this debate.
The ethical problems with including terminally ill
patients in research include their supposed vulnerability
to unrealistic expectations of benefit, their need to spend
undisturbed time with their families, and impairment by
disease or drug treatment of their capacity to comprehend
or consent to research.8–11 George Annas12 has gone so far
as to say that
Terminally ill subjectswith less than6 months to live should
be disqualified from human subjects research. Desperate,
and, therefore, too vulnerable, they are unable to dis-
tinguish research from treatment.
This assertionmakes or implies anumber of claims about
the terminally ill: that they are desperate, that they cannot
distinguish research from treatment and that they do not
value outcomes other than recovery from their illness.
These claims justify an ethical conclusion: the terminally ill
cannot benefit from participation in research and, there-
fore, should not to be invited to participate.
These are empirical claims about the thoughts and
values of the terminally ill but there is remarkably little
evidence to support them. Much of the debate about the
concerns of dying patients has been defined by, and fil-
tered through, the views of family, carers and health-care
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professionals or has involved patients who have chronic
illnesses but are not close to death.13–15Wewished, there-
fore, to investigate Annas’ empirical claim to see whether
terminally ill patients were indeed desperate for cure,
whether cure was the only outcome of research they
valued andwhether they did have difficulty distinguishing
research from treatment.
Methods
This study was a descriptive qualitative analysis of the
views of hospice patients on the problems of carrying out
research with dying patients.
Setting
The Mercy Hospice is a 20-bed hospice, part of the New
South Wales public hospital system but administered by
the Sisters of Mercy, Singleton, NSW, Australia. The Hos-
pice is themajor source of inpatient palliative care services
to the Hunter region, serving a population of approxi-
mately 500 000. In addition to its 20 inpatient beds, the
Mercy Hospice provides outreach and home care.
Newcastle is a coastal city located 160 km north of
Sydney. The majority of the population is Anglo-Celtic
in origin. There are important indigenous andnon-English
speaking communities but they are underrepresented
among Hospice patients.
Ethical considerations
This project was approved by the Hunter Area Research
Ethics Committee and Newcastle University Human
Research Ethics Committee (02/04/10/3.11 and H-324-
0502). All subjects gave informed consent, either written
or recorded.
Subjects and interviews
The data we present are derived from interviews with 9
male and 13 female patients of the palliative care service.
Their ages ranged from28 to 90 years. During the period of
the study, all patients admitted to the hospice who were
judged as being able to give informed consent to participate
were invited to do so. Patients were approached about
their participation in the interview study after their med-
ical admission was complete. They were approached on
a single occasion, by a member of the palliative care team
other than the researchers or treating physician, and given
an information sheet and time to ask any questions about
the study. Patients were offered at least 24 hours to con-
sider their participation. None of the patients approached
declined to participate and none chose to make use of the
opportunity to delay a decision.Wedidnot ask the patients
whether they had participated, or had been invited to
participate, in research studies before their admission to
the hospice.
The recorded interviews lasted between 19 and 74 min
(median 40 min). All the patients interviewed are now
dead. The interview and death were separated by less than
24 hours for five people, less than 48 hours for a further
nine people, and between 1 and 5 weeks for the others.
Eighteen of the patients had advanced malignant disease.
The diagnoses of the others, and the dates between which
data were collected, have been withheld to avoid the
possibility of identification of patients.
All the interviewswere conducted by one of the authors
(W. T.). Patients determined whether or not they would
like relatives present at the interview. The interviewer
asked open-ended, predetermined questions, structured
beforehand by the investigators to cover broad areas com-
monly considered to be concerns about palliative care
research.16,17 The responses and subsequent discussions
were recorded. Variants of these questions were intro-
duced several times during the interview to allow confirm-
ation of the concept initially put forward by the patient.
For example, ‘‘If we were doing research into hospice or
palliative care, what do you think we should do?’’ was
followed later by ‘‘What problems do we need to do
research into?’’. When this lead to responses about quality
of life, patients were asked specifically ‘‘What does quality
or quality of life mean for you?’’. When patients expressed
a desire or willingness to participate in research, we asked
about practical details such as ‘‘Who would you prefer to
ask you about being in research?’’ and ‘‘Do you think your
own doctor could ask you to be in research?’’, then ‘‘Who
else do you think could ask you?’’. The patientswere asked
‘‘Do you think you could say no to being in research?’’, ‘‘If
your doctor asked you, could you say no?’’ and ‘‘Do you
think you could say no if your nurse asked you?’’.
Patients were also asked questions about how they
would like information presented or results of research
given, such as ‘‘How much information do you think you
would need to be in research?’’ and ‘‘Howwould it be best
to give you that information?’’.
Although patients were asked about the problems that
research in the hospice should address, they were not
asked about particular research designs, with one excep-
tion.All patientswere asked if randomized controlled trials
were an appropriate design for research in the hospice.
This question was later followed up by asking ‘‘If we had
two treatments and we did not know which was better,
would it be OK to give half the patients one and half the
other?’’. The possibility of Phase I drug trials was not
specifically raised.
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To ensure the accuracy of their statements as responses
to the questions, all patients had the opportunity to review
their interviews and give additional or clarifying state-
ments and to delete comments.
Recruitment of patients continued until no new
patterns of response were observed in the most recent
interviews.
Analysis
Interviews were transcribed verbatim. All of the research-
ers read all transcripts to gain an overall understanding of
the narrative descriptions and the patients’ experiences.
The transcripts were then searched systematically for con-
forming data by each researcher.18,19 The selected state-
ments from the transcripts were compared to ensure
agreement between researchers before the next step,
the development of categories.20 Data from interviews
were then cross-checked between researchers as a means
of confirming the categories that emerged. All transcripts
were then coded on the basis of these categories. The
analysis was an iterative process involving several meet-
ings of the researcherswho reviewed transcripts independ-
ently and then met to integrate their analyses and to
resolve any disputes by extended discussion. Categories
were reviewed and modifications were made only once
agreement had been reached.19,21 Final categories were
compared to ensure that therewas no overlap and that the
themes are supported by direct quotes.22
Results
Two key areas were identified from the categories and are
illustrated here by quotation from the patients’ narratives.
The areas were (i) the value of research and the value to
the patients of research participation and (ii) practical
aspects of research. Practical aspects of research included
the way in which patients would prefer to be approached
about participation in research and the information they
believed they would need to make an informed decision
about participating in a proposed research.
The value of research and the value of
participation
Patients advanced a number of reasons for their wish to be
involved in research. We have grouped these reasons in
the categories Utility, Self-validation andAssurance. Com-
ments classified under Utility related primarily to the idea
of giving something back. Comments classified under Self-
validation related primarily to the idea that participating in
research allowed patients to see themselves and to be seen
by others as more than ’a dying person’. Assurance related
to the value of knowing that health-care workers and the
community were willing to make an effort to optimize the
care of dying patients.
Utility
Some patients said that when they had little time left, it
was important that they could use that time to do some-
thing of enduring value. They felt that participation in
research enabled them to give something back to their
families and carers and to the community. Others
expressed the view that participation in research when
they were in the unique position of knowing they were
dying gave them a special gift to give others. Some
expressed this view in narrowly technical terms – their
intimacy with pain, for example – others in terms of the
ability to make decisions without worrying about long-
term consequences. Comments illustrating this category
are given below.
Not everyone gets the chance to knowwhen they are dying,
so I say yes let me help.
I don’t want people to think I have nothing to give back,
nothing to offer.
Here you could give something back, something to help
other people.
It would be a way to give something back now before I die,
I would have done something good for the future.
Some days it seems important to give something back, other
days you might just want to leave something of yourself
behind.
I do feel I’m a bit of an expert in pain, in away that someone
who is not dying might not be.
Validation
Many patients expressed a wish to continue to participate
in a range ofmeaningful activities andnot just be the dying
person. Their weakness and fatigue made some research
activities impossible but most patients were enthusiastic
about engaging in research to the limit of their capacity.
Comments illustrating this category are given below.
It is good to research, especially when you are dying, you
don’t want to be forgotten.
Taking part in researchwould help lift that feeling that once
you cross thehospice thresholdyouarenotworthyof taking
part in ordinary things.
I want still to be a part of something, and not just someone
who has to make their will .
I think people forget we are still people, with lives outside of
being the dying person.
. if I’m part of a research I am still real, and if you doctors
are doing research I know you think of me as real too.
Terry et al.
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Assurance
Because most of the hospice patients have a primary diag-
nosis of cancer,manyhadattendedoncology clinics andhad
observed or been offered participation in radiotherapy or
chemotherapy trials. They were aware that teaching hos-
pitals customarily do research and understood this as the
pursuitofnewknowledge to improvecare.Theywereaware
also that a commitment to research is normally perceived as
an essential part of the profile of a health institution. Some
patients explicitly drew from this the conclusion that not
doing research in palliative carewas equivalent to not being
committed to optimizing care for the terminally ill. Many
understood that the knowledge that guided their treatment
had been gained through research and stated that they
would want others to benefit as they had. These patients
did not support the idea that it could be more ’ethical’ for
doctors to guess about treatment than to confront the
difficulties that arise in involving dying patients in research.
Comments illustrating this category are shown below.
.and plus if you do the experiments, it is better than only
a guess.
How do they knowwhat to give dying people for pain? That
must have been the subject of research.
I suppose we think that you already have the best pain
killers, but that might not be true might it?
. if we do experiments for all these things, then other
people might die with better quality.
I think it is a good place, and part of this place should be
research.
. when you get this far you need things to be proper, and
if there is no research here it could be terrible.
You should do it because that professor-man-doctor still
needs to learn a thing or two.
You see to me research is the only way you get down to the
real issues and get any knowledge of them, be able to make
new moves and have different ways.
How research should be carried out
What research should be undertaken in the hospice
Some patients said they would consider participating in
any kind of research but most were interested only in
research on the ‘‘disease that got me here’’ and a few only
in research in palliative care problems. When asked to
specify the most worthwhile research areas, however,
most nominated problems in palliative care. Comments
illustrating these views are shown below.
The disease, cancer especially.
You could do anything as long as it is not cruel.
I couldn’t be bothered to do research in cancer, I’m dying
now there is nothing to get from that.
It’s too late to worry about cancer.
The drugs to stop the vomiting.
. how to cope and manage the depression.
How things are going to end up.
The pain.
Dying – talk about dying and death in our society. Because if
people don’t know what to say they should research those
things.
How the request to participate should be made
Patients expressed a decided preference to be approached
about research participation and consent by a doctor or
nurse involved in their care. The most commonly given
reason for this was the effort involved in explaining their
problems to a new and unknown person. Patients were
clear that at a stage in their illness when they had accepted
dying, the involvement of a new person who might not
understand their situation was a larger concern than any
issue of possible coercion. Patients felt they had an estab-
lished relationship with their doctors and for this reason
did not have to explain again all their circumstances and
decisions to be able to participate in research. They ex-
pressed unwillingness to deal with independent research
staff who might not cope with the issues of dying. Com-
ments illustrating these views are shown below.
I am too tired to explain dying to someone new.
Trust - the one who knows you, knows what you’ve been
through.
. you get faith in your doctor, they have been through it
with you, and you don’t need to tell them you are dying.
. there isn’t time or energy to talk with people who have
hang-ups about dying.
They would have to be in it with you, not someone who
doesn’t have a clue about dying.
The doctor. Well, let me clarify that: a doctor you know
should ask you.
. because youhave to have someonewhoknows,whoyou
don’t have to go through all the adolescent stuff with, and
your doctor is the best one.
Consent
There is a commonly expressed view that terminally ill
patients may be distressed, or in pain, or frightened and
that this makes them more vulnerable than other
patients. The argument is that their vulnerability casts
doubt on the voluntariness or the autonomy of their
consent. The converse argument was put forward by
our patients, who said that there is a ’freedom’ in being
close to death so that they felt they could say precisely
what theywished andhad nothing at all to lose by voicing
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their own opinion. Comments illustrating this point are
shown below.
I wouldn’t feel obliged. If they could talk to you they
wouldn’t be worried that you couldn’t say no.
When you go to the emergency they ask you things, they
don’t think youhave stopped thinking.Whywould you not
knowwhat to say just because you are dying in the hospice.
We can just say what we think, there is nothing to lose.
. can you imagine the point of not being truthful now,
now, when I’m like this?
Iwould just sayno. Sure Iwould just sayno –nothing to lose
now.
When you are dying you can think and say anything, you
wait you’ll know what I mean.
Perhaps the most frequently expressed concern about
research with terminally ill patients is that they may
imagine that participation offers a chance of prolonging
their lives and consent only for this reason. In contrast,
many of our patients stated that they would participate in
researchonly if therewerenopossibility of it delaying their
deaths. Death was what they and their families had pre-
pared for and although a chance of cure of their disease
would, of course, be attractive, minor prolongation of life
was seen as a hazard and not as a benefit. Comments
illustrating this point are shown below.
I need the spare time, but if it was going to keep me alive I
would want to know that, because we are all here together
for my death to happen.
Well if youweregoing to last longer, thatwouldbe important,
’cause it is such hardwork getting to the point you know you
are for it, and if you turned that around, well, oh no..
. well if you are in an experiment it might make you live
longer, that would be hard, ’cause. whoever is doing the
research would need to tell you that.
. and if the drugs did work then we would all have to try
again, and keep going, and that would be hard.
Impacts on families
Another reason for concern about research in the termin-
ally ill is that research may consume some of the time
patients have to be with their friends and families. Some-
times the possibility is also raised of relatives being dis-
tressed at a trial of new treatment at a late stage. In the
interviews, patients offered information regarding both
these areas. They regarded the opportunity tomake a deci-
sion to take part in research independently of their families
as an important affirmation of their autonomy. Research
participation was also valued as a way of helping their
families to understand that they were still valuable people
and still making responsible decisions. Patients did not see
research participation as a hazard to relationships but as
a source of enrichment. Comments illustrating this point
are shown below.
.then my family could see that I gave something back.
. sometimes your family find it hard for you to be the
person they knew when you are dying, at least we could
talk about my day being in research.
. itwouldgiveus somethingelse to talk about, now thatwe
have arranged the funeral.
It would be good for the family, when the kids come in.
We can say, well, the doctor said this and that, then I
asked would it hurt, and he said ’No’ . you know, I can
tell them.
At least something else than talking about dying.
It is something else to talk about, my wife and I, at home,
we could talk about it.
Like today, I was thinking about things before you came,
what you might ask, what we might talk about. That helps.
The patients also made clear statements about the
importance of their own doctors and nurses taking respon-
sibility for explaining the research process to families.
Patients were aware that their wish to be involved in
research could worry their families but this was regarded
as having the countervailing value of obliging family
members to recognize the patient’s persisting autonomy
and individuality. Comments illustrating this point are
shown below.
It is important for your family to know, but if I decide,
I should decide.
. but if I did, I would like to take part, it would have great
meaning forme, and I thinkyou shouldhelpmydaughter to
cope with that.
It might be difficult, they are already upset, but if you tell
them it is my wish.
The final say is with the patient not the family.
A key concern to patients in the area of effects on
families was the possibility that experimental treatments
might provoke abnormal behaviour. Although the
patients did not believe that such a risk would make
the research unacceptable, they considered that behav-
ioural side-effects would be the most important issue for
discussion. Again, patients were clear that the role of
doctors was to discuss the possibility of behavioural side-
effects with the their family in order that the family be
comfortable with the patient’s decision to participate.
Comments related to this concern are shown below.
It would be only fair to know if you were going to turn blue
or become strange, so the kids would know before.
. as long as I didn’t die doing something weird, then my
family might not think it was good.
. if research would make you different, or seem different
to your family, then it would be best to know that.
Terry et al.
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. it would have to not make you too tired, toomixed up or
forget, or say things you didn’t want to say.
Randomized controlled trials
Patients did not want to participate in placebo-controlled
randomized controlled trials. However, their negative
view of placebo-controlled trials seemed to be based on
the assumption that it is known in advance that patients in
the placebo armof a trial will sufferworse outcomes. Some
patients appeared to believe that patients in the placebo
arm of a randomized controlled trial receive no active
treatment. Active comparator randomized controlled trials
appeared likely to be generally acceptable. Comments
related to randomized controlled trials are shown below.
I don’t believe in dummy pills, leading people on is not
the way.
. about placebo drugs, sometimes they know they work
the same as other drugs, so that’s not a good idea to know.
I could not just be a guinea pig. I don’t know how you
experiment for things like that.
Well you could try both and seewhich is better, but not one
that doesn’t work.
The delivery of information
Our patients, almost exclusively, wanted verbal informa-
tion. They felt that this promoted patient-focussed discus-
sion. Fatigue and some physical changes that accompany
terminal stage of illness also featured in this preference for
verbal over written information. Several commented that
because they had accepted that they were dying, they did
not want anything that was similar to the information
pamphlets they had receivedwhen theywere in the phase
of active treatment for their disease. Comments illustrating
these points are shown below.
Do you see anyone writing here? Reading things is so hard.
No long boring pamphlets or pages.
Not more forms.
Talking about things is important, talk it out but not have to
sign bits of paper.
. how tired you get reading, how it is much more
straightforward to talk about these things.
I don’t want to have to read it, reading is really too much.
I justwant someone I trust to tell it tome straight. Iwould let
you know if I needed anything else.
I do not want too much information, but I would want to
be able to ask questions.
Do not hand out a one and a half page brochure. There is
a lot more to be done than that.
I don’t think evenmy daughter would read that. No, really,
sit with you and tell you.
Discussion
Palliative care research faces obstacles arising from the
perceived practical and ethical difficulties of including ter-
minally ill patients in research. As with other controversial
aspects of palliative care, these obstacles have been framed
largely in terms of what others thought patients experi-
enced or would feel when participating in research. We
wanted to see whether the concerns that are said to dis-
tinguish palliative care as a special case, and so limit par-
ticipation,were sharedbya sampleof terminally ill patients.
We found that they were not. We suggest that current
guidelines have over-stated the difficulties of researchwith
thedyingandhavenot taken sufficient accountof thevalue
the terminally ill may place on research participation.
The patients we interviewed did not agree that there are
serious practical or ethical difficulties in the face of
researchwith the terminally ill. Theyflatly rejectedGeorge
Annas’ view, both as regards the claim that their auton-
omywas compromised and as regards the assumption that
they gain no direct benefit from research. These patients
identified interests in research, which have not been part
of previous discussions of this issue. They believed that
research participation offered what they regarded as im-
portant, immediate benefits. Certainly, they valued the
benefits to others that research offers. However, they also
identified in research participation a source of what we
have called Self-Validation: the knowledge that they could
make a useful contribution despite their terminal illness.
That is, research participation was perceived by our
patients to confer on them benefits they valued because
of, and not despite, their terminal illness.
It is important that patients had for the values and
preferences they expressed reasons that were both cogent
and relevant. For example, one reason advanced to value
the opportunity to take part in research was that it would
provide a topic of conversation with visitors. This may
seem a small hope but it cannot be argued that it is
unrealistic or desperate and its importance is for patients
alone to judge.
Our conclusions may be objected to on the grounds that
they reflect the views of only 22 people, all of whomwere
close – some very close – to death. It is certainly possible
that the views of patients terminally ill but not close to
death might differ from those of the patients we inter-
viewed. However, we believe that these particular people
are entitled to a say, each one no less than any other
individual commentator. The voices of these people bring
a perspective to the debate on research in the terminally ill
not offered by the views of less sick patients, ethicists,
hospice staff or family members. Furthermore, patients
who will die very soon have problems that patients who
are terminally ill but will die inmonths do not have. Those
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problems deserve research and that researchmust involve
patients similar to ours.
Some of the views our patients expressed deserve con-
sideration not because a dying person held them but in
their own right. The clearest example is the suggestion
that research in palliative care is important because the
dyingmay justly regard it as themost convincing evidence
that the community thinks that their problems are impor-
tant. The patients particularly valued research on pallia-
tive care problems but not because they expected that they
themselvesmight benefit. Some patients had purely altru-
istic motivations for taking part in research but others
were influenced by their awareness of what doing
research in palliative care implies about attitudes to the
care of the dying. The patients understood that research
implies approaching knowledge in an objective and hum-
ble way and saw this as a characteristic that their pro-
fessional carers needed to express. The patients
understood also that research is and is seen by the com-
munity as the key to improved care. They understood
clearly, that is, that the alternative to research is guessing
and that if we do not do research in palliative care, it may
be because we think that for the dying guessing is good
enough. We suggest that this issue has received much less
consideration than it deserves in developing guidelines for
ethical research.
Of course, patients now terminally ill are not the only
stakeholders in this discussion. However, our patients
expressed deep concern over the usurpation of their
autonomy by others – about being treated as already dead.
We suggest that for this reason it is ethically problematical
for stakeholders other than patients to base their objec-
tions to palliative care research on the ground of patients’
feelings and concern as if the patients were incapable of
speaking for themselves. This is especially the case if not all
patients have these feelings and concerns (such as a des-
perate desire for any chance of cure).
A related issue is that some ’ethical concerns’ about
research with the dying may arise from the feelings not
of patients but of researchers. For example, a National
Institutes of Health consensus conference report has raised
‘‘. an ethical question about the decency or propriety [our
italics] of intruding on patients at a particularly important
time in their lives’’.23 These feelings of shame are, we
suggest, those of the researchers. This is the language of
taboo and we do not know of any other area of medical
research that has, in recent years at least, provoked it. This
is unfortunate because one reason to value the opportu-
nity to participate in research commonly expressed by our
patients was that it would confirm that theywere still, and
were regarded as, real people: not taboo.
Many of the ideas that underlie current views about
what makes research ethical or not derive from Hans
Jonas.24 In particular, Jonas articulated the notion that
altruism is an implausible reason to take part in research
and that, therefore, research would be ethically defensible
if, and only if, the subjects shared the goals and values of
the researchers. On this basis, he drew up a hierarchy of
possible research subjects, from ’ideal’ – the researchers
themselves – to ’unacceptable’ – the dying.Wedonot have
space to argue the issue in detail and wish now only to
point out that Jonas’ claim leads to the exclusion of the
dying from research without their being consulted and
that our patients regarded this as unfair.
Our patients had clear and reasonable views about
practical aspects of information and consent. In particular,
they preferred to be approached about research by their
own physician. Research on disclosure of cancer diagnoses
gives similar results: dealing with someone you trust is the
most important aspect of communication.25 Provisions in
current guidelines restricting the involvement in the con-
sent process of a physician–investigator (e.g., Declaration
of Helsinki, Part 1, Paragraph 1026) are intended as safe-
guards butmake direct communication about the research
between the patient and someone they know and trust
impossible.
One surprising result, alsonot reflected in current guide-
lines, was that our patients regarded the possibility of an
unexpected prolongation of life as an adverse event rather
than as a benefit. This is, perhaps, the point on which our
patients’ opinions might be most plausibly supposed to
differ from those of patients less close to death. However,
the result is sufficient to show that it is simply not true that
all terminally ill patients will grasp at unrealistic hopes of
prolonging their lives. It is important in this context that
many terminally ill patients wish to shorten their lives and
some of the patients we interviewed had expressed this
desire. They, at least, are entitled to be believedwhen they
said that prolongation of their lives would be, for them, an
adverse effect of treatment.
The patients’ unwillingness to enrol in placebo-
controlled randomized controlled trials is troubling. If treat-
ment of symptoms such as pain, nausea and dyspnoea is to
advance securely, randomized controlled trials are indis-
pensable. Because the reasons patients gave for disliking
the idea of randomized controlled trials were sometimes
confused or contradictory, it is possible that they did not
understand this experimental designwell enough to judge
its acceptability. In that case, careful explanation might
make placebo-controlled randomized controlled trials
acceptable to dying patients. Active comparator trials
appeared more acceptable to our patients and may need
to be the normal design for trials in this setting. If ran-
domized controlled trials cannot bemade acceptable to the
dying, a major challenge for researchers will be to design
robust methods that are acceptable.
Terry et al.
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